The mosquito-borne Zika virus — described in recent, grim federal warnings as “not controllable by current technologies"— could become an important source of hope for a regrouped Novavax Inc. Gaithersburg-based Novavax (NASDAQ: NVAX), still recovering from stunning negative results from its phase 3 trials of its lead respiratory syncytial virus (RSV) vaccine for older adults, said this week that it had "exciting preclinical data” from its new Zika program. That opens up a significant commercial…
from http://www.bizjournals.com/baltimore/news/2016/11/14/how-the-zika-virus-could-be-a-major-bright-spot.html?ana=RSS%26s=article_search
via http://baltimorecheckbook.tumblr.com/post/153170881762
No comments:
Post a Comment